Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Atogepant
Aquipta
Routinely available
SMC (SMC2599)
07/08/2024
Indication
For the prophylaxis of migraine in adults who have at least 4 migraine days per month. SMC restriction: for patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.
Therapeutic Area
Central nervous system
Status Description
Routinely available in line with national guidance
Formulation
Tablets
Comments
Link to Advice
Advice Published
09/10/2023
SMC Submission Type
Abbreviated
SMC Status
Restricted